 |
Biomaterials and Cartilage Testing Solutions |
Company Overview
The establishment of Biomomentum Inc. is the result of a major restructuring that took place at BioSyntech Canada Inc. For over a decade, BioSyntech designed and continuously improved the Mach-1™ and the Arthro-BST™. Dr. Quenneville and Dr. Garon are former BioSyntech employees previously in charge of its Instrumentation department, where they assumed responsibility for all business activities related to the Mach-1™ and the Arthro-BST™. In 2008, BioSyntech decided to forego the development and commercialization of these products, in part, because they deviated too greatly from its core mission. Following an offer made to BioSyntech to buy these technologies, an agreement was reached in April 2009 and Biomomentum was created as a spin-out of BioSyntech. Biomomentum is a fully independent company that will continue to develop and sale the Mach-1™ and the Arthro-BST™ and has accepted responsibility for past purchases of these products.
Under the direction of Chief Executive Officer Eric Quenneville and President Martin Garon, Biomomentum aims to be a world leader in developing and marketing innovative biomedical testing solutions for biomaterials and articular cartilage. These two individuals have the capacity, expertise, passion and commitment required to effectively manage these products and to direct Biomomentum into a promising future!
Management Team
Martin Garon, PhD, President Dr. Garon holds a PhD in Biomedical Engineering from the École Polytechnique de Montréal. He completed his thesis entitle "Design and Validation of an Arthroscopic Device for the Evaluation of the Electromechanical Properties of the Articular Cartilage" under the supervision of Dr. Michael D. Buschmann, while working part time at BioSyntech as a Research Scientist. After completion of his thesis, Dr. Garon resumed a full time position at BioSyntech where he was responsible alongside Eric Quenneville of the company’s Instrumentation department. Dr. Garon was responsible for R&D, quality control and testing service activities and was involved in sales, customer service, and technical support. Over the course of his ten year professional experience, Dr. Garon has gained extensive knowledge regarding the design & development of mechanical testers and medical devices. Among numerous other realizations, he developed softwares and electronics for the Mach-1™ and the Arthro-BST™, and is co-author of three patents protecting the technologies associated with these products. |
 |
Eric Quenneville, PhD, Chief Executive Officer Always fascinated by the world of science and showing a particular interest in the areas of physics and biomechanics, Dr. Quenneville holds a PhD in Biomedical Engineering from the École Polytechnique de Montréal. While working part time at BioSyntech as a Research Scientist, he completed his thesis focussing on the development of the Arthro-BST™ and the theoretical models of the electromechanical properties of articular cartilage. Dr. Quenneville has demonstrated superior management and leadership skills throughout his academic and professional experience. Appointed Director of BioSyntech’s Instrumentation department, he recognized a potential business opportunity when BioSyntech announced its plan to terminate all corporate activities related to the Mach-1™ and Arthro-BST™. With significant expertise in business development, regulatory affairs, as well as the design & production of medical devices under strict ISO13485 control, he is equipped with skills that compliment those of his partner Martin Garon. Dr. Quenneville also has over ten years experience in the medical device industry and the drive to lead Biomomentum in the years to come. |
 |